细胞生物医学油墨与中国总医院CAR-T协议

StephenW

5. Cellular Biomedicine inks CAR-T deal with Chinese General Hospital
    By EJ Lane     

SINGAPORE--Cellular Biomedicine Group ($CBMG) has bought chimeric antigen receptor (CAR) T cell therapies from the Chinese PLA General Hospital in a deal valued at RMB12 million ($1.9 million) to be paid in three installments.

CBMG said a team led by Wei Dong Han of the hospital, also known as 301 Hospital, has conducted clinical trials of CAR-T therapies to treat CD19-positive acute lymphoblastic leukemia (ALL), CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer.

The deal includes the recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR or HER1) Immuno-Oncology patents, as well as data from Phase I and II clinical trials of these therapies and manufacturing knowledge.

CAR-T therapy involves modifying cancer patients' T cells to recognize and attack cancerous cells and tumors. These modified T cells, infused back into the patient's body, will multiply and continuously hunt for cancerous cells to guard against recurrence.

"This CAR-T cell technology acquisition further accelerates CBMG's growth in the Immuno-Oncology segment. We look forward to working with PLAGH [The General Hospital of the People's Liberation Army] as a long-term partner as we evaluate paths to commercialization," Wei, the CEO of Cellular Biomedicine Group, said in a statement.

Previously, CBMG acquired T-Cell Memory technology (Tcm), T Cell Receptor Clonality analysis technology and third generation CAR-T, anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from Agreen Biotech and Persongen Biotech.

Research and development in CAR-T therapy has been a hot trend in the past two years with many big names getting their hands on partnership and research deals. Kite Pharma ($KITE), a pioneer in the CAR-T therapy field, formed a partnership with Amgen ($AMGN) earlier this year. Pfizer ($PFE) also signed a development deal with Cellectis in 2014 for exclusive rights to their CAR-T technology platform.

Cellular Biomedicine Group is a U.S.-China biomedicine company that develops cell therapies for certain degenerative and cancerous diseases, such as knee osteoarthritis, asthma, chronic obstructive pulmonary disease and cartilage damage.

PLAGH, founded in 1953, developed into a large modern general hospital in the past half-century. It currently has 125 clinical, medical and technological departments, 4,000 patient beds and receives over 3.8 million outpatient visits, more than 110,000 admissions and oversees 65,000 operations every year.

- read the press release

StephenW

5.细胞生物医学油墨与中国总医院CAR-T协议
由EJ巷

新加坡 - 细胞生物医学集团（$ CBMG）已经收购了嵌合抗原受体来自中国解放军总医院（CAR）T细胞疗法的价值为1200万元（190万美元），分三次支付交易。

CBMG说，为首的医院，也被称为301医院魏董翰队，先后进行了CAR-T治疗的临床试验治疗CD19阳性的急性淋巴细胞白血病（ALL），CD20阳性淋巴瘤，CD30阳性霍奇金淋巴瘤与EGFR-HER1阳性的晚期肺癌。

此次交易包括重组表达载体CD19，CD20，CD30和人类表皮生长因子受体的（EGFR或HER1）免疫肿瘤的专利，以及从第一阶段的数据和这些疗法和制造知识的II期临床试验。

CAR-T治疗涉及到修改的癌症患者的T细胞识别并攻击癌细胞和肿瘤。这些修饰的T细胞，注入回患者体内，将相乘并连续猎取癌细胞以防止复发。

“这CAR-T细胞技术的收购将进一步加快CBMG的增长，免疫肿瘤学段。我们期待着与PLAGH[在解放军总医院]作为一个长期的合作伙伴，因为我们评估的商业化路径，”魏，细胞生物医学集团的CEO，在声明中说。

先前，CBMG获得T细胞记忆技术（TCM），T细胞受体克隆分析技术和第三代CAR-T，抗PD-1，从Agreen生化和生物Persongen CD19和人工APC的癌症免疫治疗技术。

研究和开发CAR-T的治疗一直是一个热门的趋势，在过去两年，很多大牌得到他们的手的合作和研究的交易。风筝制药（$ KITE），在CAR-T治疗领域的先驱，形成了安进（$ AMGN）在今年早些时候的合作伙伴关系。辉瑞制药（PFE$）还签署了开发协议与Cellectis公司在2014年的独家代理权，以自己的CAR-T技术的平台。

细胞生物医学集团是一家美国生物制药中国公司，开发细胞疗法对某些退行性和癌症疾病，如膝关节骨性关节炎，哮喘，慢性阻塞性肺疾病和软骨损伤。

PLAGH，成立于1953年，发展成为在过去半个世纪的大型现代化综合性医院。它目前拥有125个临床，医和技术部门，4000张病床，并接收超过380万门诊人次，超过11万的招生和监督，每年65000业务。

MP4

好！